$CLOV

Reynoso Jamie L. sold $18K of CLOV

Reynoso Jamie L. (CEO, Medicare Advantage) sold 4,066 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.41 on 2026-10-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Reynoso Jamie L.
Published Oct 20, 2026, 8:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 8:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Bearish
high confidence
Mentioned
$CLOV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVBearishLow
01

Why it matters

A modest insider sell may cause short‑term price softness, but the overall impact is limited given the small dollar amount.

02

Market read

Primary disclosure of a small insider sale; low trading relevance.

03

What to watch

The CEO's holdings remain large, and the sale was pre‑arranged under a 10b5‑1 plan, reducing the perceived informational value.

Relevance 2/10Novelty 2/10Timing: today

Background

Form 4 filing discloses insider transactions required by the SEC.

Company-level read

Ticker impact

$CLOVBearishHigh confidence
Context

CEO Reynoso Jamie L. sold 4,066 shares for $17,931 via a 10b5‑1 plan, reducing his stake to 2,770,351 shares.

Expected impact

likely slight downward pressure as investors digest the sell‑off

Evidence & confidence

A 10b5‑1 sale by the CEO, even at a modest $18K, can be interpreted as a lack of confidence, though the size is negligible compared with total holdings.

Market effects

Minimal impact on the health‑tech sector; the sale is company‑specific.

No broader regional effect; confined to CLOV shareholders.

Insignificant on a global scale.

Counterpoint

The sale could be routine liquidity management rather than a negative signal.

Key entities

  • Clover Health Investments, Corp.

    US‑listed health‑tech firm (ticker CLOV).

  • Reynoso Jamie L.

    CEO of Clover Health.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CLOVHigh

Why is Clover Health stock climbing 4% today?

Clover Health (CLOV) stock rose 4.3% in pre-market trading after Needham initiated coverage with a Buy rating and $6.00 price target, citing its Medicare Advantage rating and cohort economics. The company's upcoming conference presentation and Q3 earnings report also contributed to the positive sentiment. The Nasdaq Composite was up 0.5% in pre-market.

$HUMMedAI 8/10

Humana Rebounds in Medicare Advantage Star Ratings for 2027

Humana's Medicare Advantage star ratings improved significantly for 2027, with 93% of members in plans rated 4 stars or higher, up from 41% in 2026. This could generate $3B+ in additional revenue in 2028, according to TD Cowen. Alignment Healthcare saw a major decline, potentially losing $170M in revenue. CMS changed its star ratings methodology for 2027.

$CLOVHigh

Why Is Clover Health (CLOV) Stock Soaring Today

Clover Health (CLOV) stock rose 10.7% premarket after CMS awarded its PPO Medicare Advantage plans a 5-Star rating and HMO plans a 4.5-Star rating for 2027. The ratings, excluding disputed measures, boost payments and enrollment. Shares later cooled to $4.81, up 5%. CLOV is up 99.5% YTD but still below its 52-week high.

$CLOVMed

Is Clover Health Stock Too Dependent On One Group Of Members?

Clover Health Investments (CLOV) reported that nearly half of its Medicare Advantage members joined in 2025 or 2026, impacting short-term profits. Membership grew 48% YoY to 157,000, with new members accounting for 49%. Despite a 70% stock return over 12 months, CLOV's revenue declined 0.7%, and gross profit grew slower than revenue. Management raised full-year guidance but cautioned about future trends.

$CLOVMed

Clover Health Medicare Advantage PPO Plans Earn 5-Star Rating; HMO at 4.5 Stars

Clover Health's PPO Medicare Advantage plans received a 5.0 Star rating and HMO plans 4.5 Stars for 2027, impacting 2028 payments. CMS removed 20 measures for PPO plans, raising their rating. Clover's MA membership grew ~48% YoY to >157,000 members, with 98% in PPO plans. The company ranked #1 among non-SNP PPO plans with >2,000 members on core HEDIS measures, scoring 4.82 out of 5.